0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > 4-1BB

4-1BB

4-1BB Molecule Information

Name:Tumor necrosis factor receptor superfamily member 9
Target Synonym:Tumor necrosis factor receptor superfamily member 9;T-cell antigen ILA;CD_antigen=CD137;ILA;TNFRSF9;CDw137;CD137 ;T-cell antigen 4-1BB homolog;4-1BB ligand receptor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Phase ?

4-1BB Protein Product ListCompare or Buy

4-1BB Molecule Synonym Name

TNFRSF9,4-1BB,CD137,CDw137,ILA

4-1BB Molecule Background

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

4-1BB References

4-1BB Related Molecule

4-1BB Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ALG.APV-527 ALG.APV-527; ADC-1016; ATOR-1016 Preclinical Aptevo, Alligator Bioscience Cancer Details
PRS-344 PRS-344; PRS-344/ONC0055 Preclinical Pieris Pharmaceuticals Cancer Details
LVGN-6051 LVGN-6051 Phase Ⅰ Lyvgen Biopharma Holdings Limited Cancer Details
ATOR-1017 ATOR-1017 Phase Ⅰ Alligator Bioscience Metastatic cancer Details
ADG-106 ADG-106 Phase Ⅰ Adagene Solid tumours, Non-Hodgkin's lymphoma (NHL) Details
Utomilumab PF-05082566; PF-2566; PF-5082566 Phase Ⅱ Pfizer, MorphoSys Breast cancer, Oropharyngeal cancer Details
RG-7827 FAP-4-1BBL; FAP-4-1BBL FP; RG-7827 Phase Ⅰ Roche Solid tumours Details
AGEN-2373 AGEN-2373 Phase Ⅰ Agenus Cancer Details
Delolimogene mupadenorepvec LOAd-703 Phase Ⅱ Uppsala University, Lokon Pharma Colorectal cancer, Ovarian cancer, Pancreatic cancer, Biliary cancer Details
ES101 ES101 Phase Ⅰ Inhibrx, Elpiscience Solid tumours Details
MCLA-145 MCLA-145 Phase Ⅰ Incyte, Merus Solid tumours Details
Urelumab BMS-663513; BMS-66513 ,BMS663513 Phase Ⅱ Bristol-Myers Squibb, Ono Pharmaceutical B-cell lymphoma, Chronic lymphocytic leukemia (CLL), Solid tumours, Multiple myeloma (MM), Colorectal cancer, Head and neck cancer Details
PRS-343 PRS-343,PRS 343,PRS343 Phase Ⅰ Pieris Pharmaceuticals Solid tumours Details
INBRX-105 INBRX-105 Phase Ⅰ Inhibrx Solid tumours, Non-Hodgkin's lymphoma (NHL), Hodgkin lymphoma Details
GEN-1046 DuoBody-PD-L1x4-1BB; GEN1046; PD-L1x4-1BB Phase Ⅱ Genmab, BioNTech Triple negative breast cancer, Non small cell lung cancer (NSCLC), Endometrial cancer, Urothelial cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Solid tumours, Cervical carcinoma Details
MP-0310 MP-0310 Phase Ⅰ Molecular Partners Solid tumours, Cancer Details

This web search service is supported by Google Inc.

totop